摘要
目的探讨弥漫大B细胞淋巴瘤采用利妥昔单抗联合环磷酰胺、长春地辛、表柔比星及泼尼松(R-CHOP方案)治疗治疗的近远期疗效。方法选取2015年1月至2020年5月间西安医学院第二附属医院收治的80例弥漫大B细胞淋巴瘤患者,根据治疗方法不同进行分组,采用CHOP方案治疗的40例患者纳入对照组,采用R-CHOP方案治疗的40例患者纳入观察组。比较两组患者的近期疾病控制率、生存率、复发率及预后评分情况。结果观察组患者的治疗有效率为72.5%,高于对照组的50.0%,差异有统计学意义(P<0.05)。观察组患者1年后生存率为75.0%,高于对照组的52.5%,差异有统计学意义(P<0.05)。观察组患者1年后复发率为27.5%,低于对照组的50.0%,差异有统计学意义(P<0.05)。观察组患者治疗后的预后指数评分低于对照组及治疗前,差异均有统计学意义(均P<0.05)。结论针对弥漫大B细胞淋巴瘤患者,R-CHOP和CHOP两种方式均可选择,前者的近远期效果更佳,可减少疾病复发率,提高疾病生存率,使患者获得良好的预后效果。
Objective To evaluate the short-and long-term efficacy of rituximab plus cyclophospha-mide,vindesine,epirubicin and prednisone(R-CHOP)regimen versus CHOP regimen for the treatment of diffuse large B-cell lymphoma.Methods Eighty patients with diffuse large B-cell lymphoma were selected at The Second Affiliated Hospital of Xi'an Medical College from January 2015 to May 2020.They were divid-ed into two groups based on the treatment they received.Forty patients receiving R-CHOP therapy were in-cluded in an observation group and 40 patients receiving CHOP were included in a control group.The short-term disease control rate,survival rate,recurrence rate and prognosis score were compared between the two groups.Results The efficacy rate was 72.5%,in the observation group which was higher than 50.0%of the control group(P<0.05).The 1-year survival rate was 75.0%in the observation group which was sig-nificantly higher than 52.5%of the control group(P<0.05).The 1-year recurrence rate was 27.5%,which was significantly lower than 50.0%of the control group(P<0.05).The prognosis index score was significantly lower in the observation group after the treatment than in the control group and before the treat-ment(all P<0.05).Conclusion The efficacy of R-CHOP and CHOP was comparable in patients with diffuse large B-cell lymphoma.The former has better short-and long-term efficacy.It can reduce recurrence rate,improve survival rate and result in good prognosis.
作者
李巧
王珂
LI Qiao;WANG Ke(Department of Renal Endocrinology,The Second Affiliated Hospital of Xi'an Medical College,Xi'an 710038,China;Department of Respiratory and Critical Care Medicine,Xian XD Group Hospital,Xi'an 710003,China)
出处
《中国肿瘤临床与康复》
2021年第10期1162-1164,共3页
Chinese Journal of Clinical Oncology and Rehabilitation
